Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Aberrant Methylation of RASSF2A in Tumors and Plasma of Patients with Epithelial Ovarian Cancer

  • Wu, Yu (Department of Gynecology and Obstetrics, Qilu Hospital, Shandong University) ;
  • Zhang, Xian (Department of Gynecology and Obstetrics, Qilu Hospital, Shandong University) ;
  • Lin, Li (Department of Gynecology and Obstetrics, Qilu Hospital, Shandong University) ;
  • Ma, Xiao-Ping (Department of Gynecology and Obstetrics, Qilu Hospital, Shandong University) ;
  • Ma, Ying-Chun (Department of Gynecology and Obstetrics, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University) ;
  • Liu, Pei-Shu (Department of Gynecology and Obstetrics, Qilu Hospital, Shandong University)
  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The tumor suppressor gene, Ras-association domain family (RASSF)2A, is inactivated by promoter hypermethylation in many cancers. The current study was performed to evaluate the methylation status of RASSF2A in epithelial ovarian cancer (EOC) tissues and plasma, and correlations with gene expression and clinicopathologic characteristics. Method: We detected methylation of the RASSF2A gene in tissues and corresponding plasma samples from 47 EOC patients and 14 patients with benign ovarian tumors and 10 with normal ovarian tissues. The methylation status was determined by methylation-specific PCR while gene expression of mRNA was examined by RT-PCR. The EOC cell line, SKOV3, was treated with 5-aza-2'-deoxycytidine (5-azadC). Results: RASSF2A mRNA expression was significantly low in EOC tissues. The frequency of aberrant methylation of RASSF2A was 51.1% in EOC tissues and 36.2% in corresponding plasma samples, whereas such hypermethylation was not detected in the benign ovarial tumors and normal ovarian samples. The expression of RASSF2A mRNA was significantly down-regulated or lost in the methylated group compared to the unmethylated group (p<0.05). After treatment with 5-aza-dC, RASSF2A mRNA expression was significantly restored in the Skov3 cell line. Conclusion: Epigenetic inactivation of RASSF2A through aberrant promoter methylation may play an important role in the pathogenesis of EOC. Methylation of the RASSF2A gene in plasma may be a valuable molecular marker for the early detection of EOC.

Keywords

References

  1. Agathanggelous A, Honorio S, Macartney DP, et al. (2001). Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 1509-18. https://doi.org/10.1038/sj.onc.1204175
  2. Akino K, Toyota M, Suzuki H, et al (2005). The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology, 129, 156-69. https://doi.org/10.1053/j.gastro.2005.03.051
  3. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, et al (2003). Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol, 189, 1120-7. https://doi.org/10.1067/S0002-9378(03)00579-9
  4. Bhagat R, Chadaga S, Premalata CS, et al (2012). Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development. Cell Oncol, 35, 473-9. https://doi.org/10.1007/s13402-012-0106-4
  5. BonDurant AE, Huang Z, Whitaker RS, et al (2011). Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol, 123, 581-7. https://doi.org/10.1016/j.ygyno.2011.08.029
  6. Cannistra SA. (1993). Cancer of the ovary. N Engl Med, 329, 1550-9. https://doi.org/10.1056/NEJM199311183292108
  7. Choi YL, Kang SY, Shin YK, et al (2006). Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch, 448, 331-6. https://doi.org/10.1007/s00428-005-0091-3
  8. Costello JF, Plass C. (2001). Methylation matters. J Med Gent, 38, 285-303. https://doi.org/10.1136/jmg.38.5.285
  9. Dammann R, Li C, Yoon JH, et al (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 25, 315-9. https://doi.org/10.1038/77083
  10. Dammann R, Yang G, Pfeifer GP. (2001). Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res, 61, 3105-9.
  11. Darehdori AS, Dastjerdi MN, Dahim H, et al (2012). Lack of significance of the BRCA2 promoter methylation status in different genotypes of the MTHFR a1298c polymorphism in ovarian cancer cases in Iran. Asian Pac J Cancer Prev, 13, 1833-6. https://doi.org/10.7314/APJCP.2012.13.5.1833
  12. Dong YQ, Liang JS, Zhu SB, et al (2013). Effect of 5-aza-2'-deoxycytidine on cell proliferation of non-small cell lung cancer cell line A549 cells and expression of the TFPI-2 gene. Asian Pac J Cancer Prev, 14, 4421-6. https://doi.org/10.7314/APJCP.2013.14.7.4421
  13. Endoh M, Tamura G, Honda T, et al (2005). RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer, 93, 1395-9. https://doi.org/10.1038/sj.bjc.6602854
  14. Herman JG, Baylin SB. (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 349, 2042-54. https://doi.org/10.1056/NEJMra023075
  15. Hesson LB, Wilson R, Morton D, et al (2005). CpG island promoter hypermethylation of a novel Ras effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutuation. Oncogene, 24, 3987-94. https://doi.org/10.1038/sj.onc.1208566
  16. Ibanez de Caceres I, Battagli C, Esteller M, et al (2004). Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res, 64, 6476-81. https://doi.org/10.1158/0008-5472.CAN-04-1529
  17. Jones PA, Baylin SB. (2007). The epigenomics of cancer. Cell, 128, 683-92. https://doi.org/10.1016/j.cell.2007.01.029
  18. Jones PA, Laird PW. (1999). Cancer epigenetics comes of age. Nat Genet, 21, 163-7. https://doi.org/10.1038/5947
  19. Leon SA, Shapiro B, Sklaroff DM, et al (1997). Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res, 37, 646-50.
  20. Liao X, Siu MK, Chan KY, et al (2008). Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carciongenesis. Int J Cancer, 123, 296-302. https://doi.org/10.1002/ijc.23494
  21. Liu WJ, Tan XH, Guo BP, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data. Asian Pac J Cancer Prev, 14, 3719-24. https://doi.org/10.7314/APJCP.2013.14.6.3719
  22. Makarla PB, Saboorian MH, Ashfaq R, et al (2005). Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res, 11, 5365-9. https://doi.org/10.1158/1078-0432.CCR-04-2455
  23. Ma L, Guo Q, Ma Y, et al (2009). Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers. Eur J Gynaecol Oncol, 30, 370-4.
  24. Maruyuma R, Akino K, toyata M, et al (2008). Cytopalsmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis, 29, 1312-8. https://doi.org/10.1093/carcin/bgn060
  25. Mutskov VJ, Farrell CM, Wade PA, et al (2002). The barrier function of an insulator couples high histone acetylation levels with specific protection of promoter DNA from methylation. Genes Dev, 16, 1540-54. https://doi.org/10.1101/gad.988502
  26. Park HW, Kang HC, Kim IJ, et al (2007). Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer, 120, 7-12. https://doi.org/10.1002/ijc.22276
  27. Perlin E, Moquin RB. (1972). Serum DNA levels in patients with malignant disease. Am J Clin Pathol, 58, 601-2.
  28. Qiu H, Zhu J, Yu J, et al (2011). SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated. Asian Pac J Cancer Prev, 12, 791-5.
  29. Rathi A, Virmani AK, Schorge JO, et al (2002). Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res, 8, 3324-31.
  30. Ren J, He W, Zhang R, et al (2009). RASSF2A promoter methylation in hepatitis B virus-related hepatocellular cancinogenesis and its correlation with elevated serum ${\alpha}$-fetoprotein level. J Huazhong Univ Sci Technol [Med Sci], 29, 309-12. https://doi.org/10.1007/s11596-009-0309-8
  31. Richter AM, Pfeifer GP, Dammann RH. (2009). The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta, 1796, 114-28.
  32. Schlaerth AC, Chi DS, Poynor EA, et al (2009). Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. Int J Gynecol Cancer, 19, 1199-204. https://doi.org/10.1111/IGC.0b013e31819d82c3
  33. Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics. 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  34. Spandidos DA, Sourvinos G, Tsatsanis C, et al (2002). Normal ras genes: their onco-suppressor and pro-apoptotic functions. Int J Oncol, 21, 237-41.
  35. Vos MD, Ellis CA, Elam C, et al (2003). RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J. Biol Chem, 278, 28045-51. https://doi.org/10.1074/jbc.M300554200
  36. Wei SH, Balch C, Paik HH, et al (2006). Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res, 12, 2788-94. https://doi.org/10.1158/1078-0432.CCR-05-1551
  37. Yoon JH, Dammann R, Pfeifer GP. (2001). Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer, 94, 212-7. https://doi.org/10.1002/ijc.1466
  38. Zhang Z, Sun D, Van do N, et al (2007). Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer, 120, 32-8. https://doi.org/10.1002/ijc.22185
  39. Zhang Q, Hu G, Yang Q, et al (2013). A multiple methylationsepcific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol, 4, 01-8.

Cited by

  1. Ovarian Cancer: Interplay of Vitamin D Signaling and miRNA Action vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3359
  2. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma vol.55, pp.11, 2015, https://doi.org/10.1002/mc.22416
  3. Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3337
  4. Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma vol.33, pp.1, 2016, https://doi.org/10.1007/s10585-015-9759-5
  5. Methylation status and protein expression of RASSF1A in endometriosis vol.11, pp.6, 2016, https://doi.org/10.3892/ol.2016.4512